Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer
James Chih‐Hsin Yang(National Taiwan University Hospital), Gongyan Chen, Filippo de Marinis(Carlo Forlanini Hospital), Rina Hui(The University of Sydney), Shun Lü(Shanghai Jiao Tong University), Ki Hyeong Lee(Chungbuk National University Hospital), Pedro Rafael Martins De Marchi, David Vicente(Hospital Universitario Virgen Macarena), Natasha B. Leighl(Princess Margaret Cancer Centre), Takako Inoue(Osaka International Cancer Institute), Dae Ho Lee(Asan Medical Center), Andrew Mant, Cheng‐Ta Yang(Shanghai Medical College of Fudan University), Jason Agulnik, Emmanuel de la Mora Jimenez(Instituto Jalisciense de Cancerología), Leandro Brust, M. Pérol(Centre Léon Bérard), Eiji Iwama(Kyushu University), Eiki Ichihara(Okayama University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Parneet Cheema(University of Toronto), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Sérgio Jobim Azevedo(Hospital de Clínicas de Porto Alegre), M. Catherine Pietanza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Fábio Franke(National Cancer Center), Jerónimo Rafael Rodríguez‐Cid(Hospital Médica Sur), Diana Chirovsky(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michael Boyer(Chris O’Brien Lifehouse), Gustavo Werutsky(European Organisation for Research and Treatment of Cancer), Ambika Parmar, Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Sagun Parakh(Australian Research Council), Ines B. Menjak, Thomas John(Austin Hospital), Mark Doherty, Li Zhang(Gdańsk Medical University), Jong‐Seok Lee(Seoul National University Bundang Hospital), Yun Fan(Zhejiang Cancer Hospital), Ying Cheng, Zhigang Han, Yiwen Luo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Jiuwei Cui(Jilin University), Niyati Bhagwati(Merck & Co., Inc., Rahway, NJ, USA (United States)), Joilda Batista De Almeida Rego, Gustavo Dix Junqueira, Phillip Parente(Cornell University), Mark E. Wong, Fernanda Maris Peria
Cited by 137
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k